Government Delays Stall Life-Saving Medicines in Pakistan, leaving patients without timely access to advanced treatments. These delays affect critical therapies, including cancer treatment drugs, heart disease medications, and hypertension medications. Patients and healthcare providers struggle as the backlog of approvals grows, and the healthcare system faces increasing challenges.
The main cause of this issue is prolonged government approval of drugs. Pharmaceutical companies in Pakistan submit applications to the Drug Regulatory Authority of Pakistan (DRAP), but medicine price notifications often remain pending for months. Even when DRAP and the drug pricing committee approve prices, final authorization from the federal cabinet can take much longer. This slows local drug market entry and prevents modern treatment availability for those who need it most.
Delays in life-saving therapies not only impact patient health but also increase the risk of unregulated or smuggled drugs entering the market. Experts warn that such gaps in access can worsen medical conditions and raise treatment costs. According to the Pakistan Pharmaceutical Manufacturers Association, over 60 new advanced medicines in Pakistan are waiting for approval, leaving thousands of patients in urgent need.
The government must act to streamline the new medicine approval process. Clear policies distinguishing price determination from price increases could reduce confusion and speed up approvals. Encouraging local production of essential therapies and collaborating with international pharmaceutical companies can also improve patient access to treatment.
In conclusion, government delays stall life-saving medicines in Pakistan, threatening patient health and putting pressure on the healthcare system. Immediate policy reform and faster approvals are crucial to provide timely access to life-saving drugs.
